EUVIMEDEUVIMED entdecken
Crossref

Structure-guided optimization of benzo[d]oxazole-based NAMPT inhibitors against NAPRT-deficient cancers

Yeji Kim, Jooyoung Lee, Hocheol Lim, Myung-Jeom Ryu, Jee Sun Yang, Chang-Mok Oh, Chulho Lee, Hyun Seok Kim, Gyoonhee Han

Bioorganic Chemistry · 2026-11 · 184 · 110699

DOI: 10.1016/j.bioorg.2026.110699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-11. Verfasst von Yeji Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea. Hauptthemen laut MEDLINE: Nicotinamide Phosphoribosyltransferase, Antineoplastic Agents, Enzyme Inhibitors, Cytokines. Die Arbeit nennt 44 Literaturangaben. Gefördert von: National Research Foundation of Korea, Korea Institute for Advancement of Technology, Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nicotinamide phosphoribosyltransferase (NAMPT) has emerged as a therapeutic target for exploiting the metabolic vulnerability of NAPRT-deficient cancers. In this study, we developed benzo[d]oxazole-based NAMPT inhibitors through structure-guided optimization from SW008135, involving sequential modifications of the distal substituent, linker architecture, and benzo[d]oxazole scaffold. Structure-activity relationship analysis identified the C position of the benzo[d]oxazole ring as a favorable site for structural elaboration, with expansion of the fused aromatic system leading to the identification of 3o as the most potent derivative. Compound 3o exhibited an antiproliferative IC₅₀ of 5.78 nM in H322 cells, representing an approximately 587-fold improvement over SW008135. Importantly, this enhancement was accompanied by preferential antiproliferative activity against NAPRT-deficient NSCLC cells, with IC₅₀ values ranging from 5.78 to 38.83 nM across three NAPRT-deficient cell lines. Comparative AUC and ΔAUC analyses identified 3o as the most selective derivative within the synthesized series, while its limited activity in NAPRT-positive HBEC30 cells was consistent with the observed NAPRT-associated selectivity. Biochemical assays confirmed direct NAMPT inhibition by 3o (IC₅₀ = 86.72 ± 17.51 nM), whereas molecular docking and molecular dynamics simulations revealed differences in NAMPT-ligand interaction patterns and persistence compared with reference inhibitors SW008135 and FK866. Further pharmacological evaluation showed favorable human liver microsomal stability, although limited aqueous solubility and extensive plasma protein binding remained important limitations. Overall, the identification of 3o demonstrates the potential of structure-guided benzo[d]oxazole scaffold optimization through the integration of in silico analyses and in vitro biological evaluations for the development of NAMPT inhibitors targeting NAPRT-deficient cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nicotinamide PhosphoribosyltransferaseAntineoplastic AgentsEnzyme InhibitorsCytokinesBenzoxazolesHumansStructure-Activity RelationshipCell ProliferationCell Line, TumorDrug Screening Assays, AntitumorMolecular StructureDose-Response Relationship, DrugMolecular Docking Simulation

Stichwörter der Autor:innen

Benzo[d]oxazoleMolecular dynamics simulationNAMPTNAMPT inhibitorNAPRT deficiencyNon-small cell lung cancerStructure-guided drug designStructure–activity relationshipSynthetic lethality

Substanzen

Nicotinamide PhosphoribosyltransferaseAntineoplastic AgentsEnzyme InhibitorsCytokinesBenzoxazolesnicotinamide phosphoribosyltransferase, human

Autor:innen und Institutionen

  • Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea.
  • Checkmate Therapeutics Inc., Seoul 07631, Republic of Korea.
  • College of Advanced Bio-Convergent Engineering, Ajou University, Suwon 16499, Republic of Korea.
  • Amicogen Inc., Jinju 52840, Republic of Korea.
  • CK Regeon Inc., Seoul 03722, Republic of Korea.
  • SK Chemicals Co., Ltd., 310 Pangyo-Ro, Bundang-Gu, Seongnam-Si, Gyeonggi-Do 13494, Republic of Korea.

Förderung

  • National Research Foundation of Korea
  • Korea Institute for Advancement of Technology
  • Korea Health Industry Development Institute

Zitieren

APA

Kim, Y., Lee, J., Lim, H., Ryu, M. J., Yang, J. S., Oh, C. M., Lee, C., Kim, H. S., & Han, G. (2026). Structure-guided optimization of benzo[d]oxazole-based NAMPT inhibitors against NAPRT-deficient cancers. Bioorganic Chemistry, 184, 110699. https://doi.org/10.1016/j.bioorg.2026.110699

Vancouver

Kim Y, Lee J, Lim H, Ryu MJ, Yang JS, Oh CM, et al. Structure-guided optimization of benzo[d]oxazole-based NAMPT inhibitors against NAPRT-deficient cancers. Bioorganic Chemistry. 2026;184:110699. doi:10.1016/j.bioorg.2026.110699

BibTeX
@article{Kim2026,
  author = {Kim, Yeji and Lee, Jooyoung and Lim, Hocheol and Ryu, Myung-Jeom and Yang, Jee Sun and Oh, Chang-Mok and Lee, Chulho and Kim, Hyun Seok and Han, Gyoonhee},
  title = {Structure-guided optimization of benzo[d]oxazole-based NAMPT inhibitors against NAPRT-deficient cancers},
  journal = {Bioorganic Chemistry},
  year = {2026},
  volume = {184},
  pages = {110699},
  doi = {10.1016/j.bioorg.2026.110699}
}
Kostenlos starten →